Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock-option grants to four non-executive employees totaling 20,800 options, approved May 1, 2026 under the 2018 Equity Inducement Plan.
The options carry a 10-year term, an exercise price of $69.42 (Nasdaq close May 1, 2026) and a standard 1/4 then monthly vesting schedule.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SYRE
-0.42%
40 alerts
-0.42%Session close to close
-3.1%Trough in 3 hr 33 min
$6.15BMarket Cap
0.8xRel. Volume
In the May 4 session, SYRE declined 0.42%, reflecting a mild negative market reaction.
Argus tracked a trough of -3.1% from its starting point during tracking.
Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility.
This announcement details routine employee equity inducement awards covering 20,800 options at an ex...
Analysis
This announcement details routine employee equity inducement awards covering 20,800 options at an exercise price of $69.42, granted under Spyre’s 2018 plan and aligned with Nasdaq Listing Rule 5635(c)(4). In context, Spyre recently raised over $400M and reported strong SPY001 Phase 2 data while maintaining about $741M in cash and securities. Investors may watch future use of the $500M shelf and additional trial updates as more material catalysts than these grants.
Key Figures
Inducement options granted:20,800 sharesOption exercise price:$69.42Current share price:$69.42+5 more
8 metrics
Inducement options granted20,800 sharesStock options to four non-executive employees under 2018 Equity Inducement Plan
Option exercise price$69.42Exercise price equal to SYRE Nasdaq closing price on May 1, 2026
Current share price$69.42Latest price in market context, up 3.56% over last 24 hours
Market capitalization$5,919,979,740Equity value based on latest share price
Shelf registration size$500,000,000Maximum aggregate offering under February 19, 2026 Form S-3 shelf
Cash & securities$741,000,000Preliminary cash, cash equivalents and marketable securities as of March 31, 2026
Public offering size$403,000,000Total public offering price for 6,500,000 shares at $62.00 (April 15, 2026 424B5)
Offering gross proceeds$463,500,000Gross proceeds from offering including 975,000-share over-allotment (April 16, 2026 8-K)
Set date and call details to report SPY001 Part A topline results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news shows positive price reactions to both clinical milestones and sizable equity offerings, suggesting strong demand that has outweighed typical dilution concerns.
Recent Company History
Over the last several weeks, Spyre’s trajectory has been defined by positive clinical data and significant capital raises. On April 13, Part A SKYLINE results for SPY001 showed strong efficacy and safety, followed by conference-call logistics news the same day. Between April 13–16, Spyre launched and closed successive offerings totaling over $400M in proceeds, each met with positive price moves. Today’s inducement option grants fit into this broader expansion phase but are operationally minor versus earlier financings and trial data.
"to four non-executive employees as equity inducement awards under the Spyre"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
nasdaq listing rule 5635(c)(4)regulatory
"of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"approved the grant of stock options to purchase an aggregate of 20,800 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,800 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on May 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $69.42, the closing price per share of Spyre's common stock as reported by Nasdaq on May 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
What did Spyre Therapeutics (SYRE) announce on May 1, 2026 regarding inducement awards?
Spyre granted an aggregate of 20,800 stock options to four non-executive employees. According to the company, the grants were approved May 1, 2026 under the 2018 Equity Inducement Plan with a 10-year term and $69.42 exercise price.
What is the exercise price and term for the SYRE inducement stock options?
The options carry an exercise price of $69.42 and a 10-year term. According to the company, the $69.42 price equals Spyre's Nasdaq closing price on May 1, 2026 and the options expire ten years from grant.
How do the Spyre (SYRE) options vest for the new employees?
Vesting is one-fourth of shares after the first anniversary, then one-forty-eighth monthly thereafter. According to the company, vesting is subject to continuous service through each applicable vesting date.
Why were the stock options granted as inducement awards under Nasdaq rules for SYRE?
The options were material to each employee's acceptance of employment and granted under Nasdaq Listing Rule 5635(c)(4). According to the company, that rule permits equity inducements for new hires approved by an independent compensation committee.
Are the SYRE inducement options subject to any plan terms or conditions?
Yes, the options are subject to the terms of Spyre's 2018 Equity Inducement Plan as amended. According to the company, all grants follow the plan's provisions, including exercise, vesting and forfeiture conditions.
